Competing to Collaborate: How Federated Learning Is Quietly Reshaping Pharma's AI Race
There's an old pharmaceutical paradox: the data that would most accelerate drug discovery is precisely the data companies will never share. Every major player in the industry has a mountain of data on compounds tested, assay results, and clinical observations – all of which could be a treasure trove for machine learning models. However, sharing this data with a competitor? Out of the question. Federated Learning (FL) is a technology that's silently eliminating this paradox. It allows drug discovery leaders to collaborate on machine learning model development without sharing data with their competitors – not even a peek. And 2024 and 2025 saw this technology go from proof-of-concept to production. Federated Learning (FL) is the technology quietly dismantling that paradox. It lets companies collaborate on AI model training without ever moving, exposing, or even glimpsing each other's underlying data. And in 2024–2025, the industry moved from proof-of-concept to real-world...